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INTRODUCTION
Prematurity represents a serious problem
for healthcare services throughout the world.
Respiratory distress syndrome continues to be
the most important pulmonary problem dur-
ing the neonatal period, affecting a large
number of premature infants. In Brazil, res-
piratory distress syndrome together with other
respiratory problems was responsible for 44%
of deaths due to perinatal affections in the year
1990, and this number increased to 49% in
1995. Despite the widespread use of exog-
enous surfactants for respiratory distress syn-
drome, mortality caused by this respiratory
affection in Brazilian intensive care units con-
tinues to be four to five times greater than in
developed countries.1
There are some relatively simple obstetric
procedures for preventing the neonatal com-
plications that lead to increases in morbidity,
mortality and sequelae among survivors. The
use of antenatal corticosteroids for fetal matu-
ration is one of these procedures. 2
The initial studies on antenatal
corticosteroids had their scientific grounding in
investigations on animals done in the 1960s. In
these, it was noted that glucocorticoids were ca-
pable of accelerating the development process
of organs and systems, especially for the lungs.3
In 1972, Liggins & Howie4 demonstrated a re-
duction in the incidence of respiratory distress
syndrome among human neonates that received
antenatal corticosteroids, and a reduction in their
mortality. After this classic study, many others
were made.5-16 Nevertheless, these studies were
not enough to stimulate the routine use of ante-
natal corticosteroids in obstetric practice. This
situation persisted until 1990, when Crowley et
al.17 brought together 12 controlled studies of
good methodological quality in a meta-analysis.
These studies involved the use of antenatal
corticosteroids or placebo on around 3,000 pa-
tients, and the meta-analysis demonstrated that
antenatal medication promoted a 50% reduc-
tion in the incidence of respiratory distress syn-
drome and 40% in neonatal mortality, as well as
a reduction in the occurrence of peri-intraven-
tricular hemorrhage in the newborns treated.
Soon afterwards, in 1994, the National Insti-
tutes of Health brought together several special-
ists involved in perinatology and established a
consensus18 on the use of antenatal
corticosteroids. This was an attempt to stimu-
late and disseminate the use of antenatal ster-
oids in clinical practice.
Corticosteroids interact with specific
receptor proteins in the target tissue so as to
regulate the expression of the genes that are re-
sponsive to corticosteroids. Thus, the levels and
disposition of the proteins synthesized by the
various target tissues are altered.19 In this way,
corticosteroids assist in achieving a successful
transition from fetal to extra-uterine life, accel-
erating fetal maturation as a whole.20-27 The
acceleration of lung development leads to a re-
duction in the incidence of respiratory distress
syndrome and its severity.17,28-30 The structural
and biochemical alterations induced by
corticosteroids translate into a diminution of
the need for and duration of mechanical venti-
lation for newborns with respiratory insuffi-
ciency.31-33 In developed countries, a significant
reduction has also been observed in deaths from
respiratory diseases through the widespread use
of antenatal corticosteroids.34 This antenatal
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therapy should be considered not only because
of the pulmonary maturation, but also for its
protective role in the premature infant’s brain.
The use of antenatal corticosteroids leads to
substantial reduction in the incidence of peri-
intraventricular hemorrhage17,28-30 and its severe
forms35 that produce important neurological
sequelae among the survivors.36 In addition to
this, the cardiovascular stabilization promoted
by corticosteroids and the modifications in re-
nal function are essential for the extra-uterine
survival of extremely premature infants.37 An-
tenatal corticosteroid therapy exercises an in-
fluence on practically all the organs and sys-
tems of the fetus and avoids or eases the com-
plications most commonly associated with pre-
maturity.
In the United States, the use of antenatal
corticosteroids on newborns with a birth weight
of less than 1,500 g increased from levels close
to 20% at the start of the 1990s to 60% in
1995.38 At present, antenatal corticosteroid uti-
lization covers around 70% of the newborns
of very low weight at 14 American centers that
belong to the NICHD Neonatal Research Net-
work.39 In Latin America, the few data avail-
able indicate that corticosteroids are used on
around 30% of the pregnant women with pre-
mature deliveries.40-42 In Brazil, there are some
reports of antenatal corticosteroid use for in-
ducing fetal lung maturation. In a study cover-
ing seven public maternity hospitals in Rio de
Janeiro, the antenatal corticosteroid utilization
was 4% and 2% for patients with gestational
ages of under 34 and up to 36 weeks, respec-
tively.2 Another survey was done on premature
infants with birth weights of under 1,500 g,
born in eight neonatal intensive care units at
university hospital referral facilities in various
Brazilian states, during the period from March
1998 to December 1999. This showed an av-
erage utilization rate for antenatal
corticosteroids of 29%, varying between 10%
and 39% across the eight facilities.43 In other
words, the scarce data available with respect to
the frequency of antenatal corticosteroid utili-
zation in our environment reveal that this thera-
peutic strategy has been underused, in the light
of its potential benefits.
In view of the potential benefits of ante-
natal corticosteroid therapy and the sparse-
ness of publications regarding its use in Bra-
zil, there was a need for the present study. Its
general objective was to evaluate the effective-
ness of antenatal corticosteroids on newborns
with gestational ages of less than 34 weeks.
The specific endpoints were to evaluate
whether antenatal corticosteroids diminished
the incidence of respiratory distress syndrome
and the occurrence of intra-hospital deaths
among Brazilian premature infants.
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METHODS
Design, setting and sample
The present study was formed by a retro-
spective cohort based on an analysis of the
records of patients with a gestational age of
less than 34 weeks and their respective moth-
ers. These patients were born during the pe-
riod from January 1988 to December 1998,
in Hospital São Paulo, of Universidade Fed-
eral de São Paulo. The research protocol was
approved by the Committee for Ethics in Re-
search of the institution.
Inclusion and exclusion criteria
For the evaluation of antenatal corticos-
teroid use and the occurrence of respiratory
distress syndrome and intra-hospital deaths,
patients that fulfilled the following criteria
were included in the study:
• Newborns whose mothers were exposed
to antenatal corticosteroid therapy, in ac-
cordance with the individual decision of
the obstetrician;
• Newborns whose mothers were not ex-
posed to any dose of antenatal corticos-
teroids. The neonates in this group were
chosen to match with exposed neonates,
according to sex (same as the exposed
neonate), gestational age (within about
two weeks), birth weight (within approxi-
mately 250 g) and the time of the birth
(within up to 100 days of the birth of the
exposed newborn).
The criteria for excluding the patient
from the population studied were:
• Presence of major congenital malforma-
tions44
• Use of corticosteroids by the pregnant
mother for a purpose other than fetal
maturation
• Antenatal corticosteroid use occurring
more than seven days before the delivery.
Variables and Data obtained
The records of the mothers and their
newborns were researched to obtain the fol-
lowing data.
Demographic variables for the mother: age
and race; pre-existing clinical and obstetric dis-
eases in the present pregnancy; presence of pre-
natal care (more than four visits); presence of
premature delivery labor; need for tocolytics;
presence of prolonged rupture of membranes
(more than 24 hours) and chorioamnionitis.45
Steroid therapy for the mother: an analysis
was made of the drugs utilized (betamethasone,
dexamethasone or hydrocortisone), the number
of doses applied, the number of hours or days
between the first dose and the time of delivery,
and the number of courses received by the preg-
nant woman. A complete course was defined
as the use of two doses of betamethasone or
four doses of dexamethasone or hydrocortisone,
between 24 hours and 7 days prior to delivery.
An incomplete course was defined as one dose
of betamethasone or less than four doses of dex-
amethasone or hydrocortisone within seven
days prior to delivery or, when any dose of cor-
ticosteroid was utilized during the 24 hours that
preceded the delivery. Multiple courses were
considered to have occurred when two or more
complete courses of antenatal corticosteroids
were administered to the patient.
Demographic variables for the newborns:
data were obtained on the need for resuscita-
tion in the delivery room,46 the Apgar score47
at the first and fifth minute of life, sex, birth
weight and gestational age, determined from
obstetric data or from a neonatal examina-
tion,48-50 as well as the classification of the new-
born51 and presence of twinning.
Clinical neonatal outcomes:
• Respiratory distress syndrome: respiratory
distress starting within six hours of life and
typical radiological findings.52, 53
• Intra-hospital deaths: an analysis was
made of the age when death occurred and
its immediate cause according to the neo-
natologist in charge of the patient or the
pathologist who did the necropsy.
• Use of surfactants: among the patients with
a diagnosis of respiratory distress syndrome,
the number of doses and type of exogenous
surfactant utilized were verified.
• Mechanical ventilation: the need for and
duration of mechanical ventilation were
evaluated.
• Bronchopulmonary dysplasia: defined as
oxygen need at 28 days of life, with fixed
radiological alterations.54
• Peri-intraventricular hemorrhage: the
method utilized for its diagnosis was head
ultrasonography, performed at the bed-
side, generally on the fourth, tenth and
thirtieth days of life, and classified accord-
ing to Papile et al.55
• Necrotizing enterocolitis: the presence of a
clinical-radiological or surgical diagnosis of
necrotizing enterocolitis was verified, and
classified according to Walsh & Kliegman.56
Statistical Analysis
The chi-squared 57 or Fisher Exact57 tests
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were applied for comparing category data be-
tween the antenatal corticosteroid and non-
antenatal corticosteroid groups. Student’s t
test58 was utilized for the numerical data. Be-
cause the length of stay in the hospital, the
duration of mechanical ventilation and the
number of doses of surfactant did not present
normal distributions, these were compared
between the groups by the Mann-Whitney
test.59 The comparison between clinical out-
comes for the two groups studied was made
by the calculation of the odds ratio (OR) and
its confidence interval (CI).57 In all the tests,
the level of significance was set at 0.05.
For the paired analysis of the patients with
and without antenatal corticosteroids during
the period studied, an initial analysis was done
on 244 newborns whose mothers had received
corticosteroids for fetal maturation not more
than seven days before the delivery. However,
it was only possible to match up 205 newborns
(84%). The remaining 39 neonates, for whom
it was not possible to find a matching patient
not exposed to antenatal corticosteroids within
the criteria established above, were excluded
from this first analysis. The power of the sam-
ple (205 newborns exposed to antenatal
corticosteroids and 205 not exposed) was cal-
culated for the occurrence of respiratory dis-
tress syndrome and intra-hospital deaths as
99% and 76%, respectively.
To analyze what the role of antenatal
corticosteroids was, among the various peri-
natal factors that could have interfered in the
occurrence of respiratory distress syndrome
and intra-hospital death, logistic regression
models were made,60 utilizing the Statistical
Package for the Social Sciences (SPSS) soft-
ware, version 8.0. This study included the 244
patients whose mothers utilized antenatal
corticosteroids, along with the 205 who did
not utilize this therapy, for the period from
January 1988 to December 1998.
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RESULTS
During the period of the study, 1,051 pre-
mature infants were born with a gestational
age of less than 34 weeks, after excluding those
with major congenital anomalies. Of these
1,051 patients, it was not possible to recover
the records of 28 of the mothers, and so the
review was done on 1,023 (99.5%) of the
records, for verifying the inclusion and exclu-
sion criteria of the study. Of the 1,023 records,
it was observed that 258 mothers made use of
corticosteroids to induce fetal maturation not
more than seven days before the delivery and
of these, 244 records (95%) of the respective
newborns were recovered.
The neonates forming the group that did
not undergo antenatal corticosteroid therapy
were chosen from among the 1,023 patients
whose records were recovered, excluding the
258 newborns who utilized antenatal
corticosteroids. For this, as described earlier, the
neonates exposed to antenatal corticosteroids
were paired with non-exposed neonates. The
majority of the 39 newborns for whom it was
not possible to find a pair were born in the
years 1997 and 1998, when the rate of utili-
zation of antenatal corticosteroids by the ob-
stetrics team increased. We emphasize that the
use of antenatal corticosteroids went on in-
creasing gradually, varying from 5-10% in the
years 1988 and 1989 and reaching half of the
pregnant mothers in premature delivery labor
in the years 1997 and 1998.
The great majority of the mothers (241 out
of 244, i.e. 99%) received betamethasone for
the induction of fetal maturation. With regard
to the number of doses of betamethasone, it
was observed that 50 patients (20%) received
only one dose, 125 (51%) two doses and 69
(28%) more than two doses. With regard to
the interval between the administration of the
first dose of the medication and the delivery,
53 pregnant women (22%) received the ster-
oid less than 24 hours before the delivery and
191 (78%) between 24 hours and seven days
prior to delivery. At least one complete course
of antenatal corticosteroids was accomplished
by 184 pregnant women (75%), and 60 (25%)
received one incomplete course of treatment.
Among those who received the complete
course, a single course of antenatal corticos-
teroids was used on 135 (73%) and multiple
courses on 49 (27%).
The comparison of the maternal data be-
tween the newborns who made use of the an-
tenatal therapy and those who did not is to be
found in Table 1. In the group exposed to an-
tenatal corticosteroids, there was a higher fre-
quency of pregnant women presenting preg-
nancy-induced hypertension, a greater number
of cesarean sections, a greater need for tocolytics
and a longer length of stay in the hospital.
With regard to the demographic charac-
teristics of the newborns who received ante-
natal corticosteroids and those that did not,
Table 1 demonstrates an average weight of
1289.5 g and a gestational age of 31 weeks
for the two groups. The Apgar score at one
minute was greater for the neonates with an-
tenatal corticosteroids and there was a pre-
dominance of newborns that were small for
gestational age in the group exposed to cor-
ticosteroids.
The comparison of the main clinical out-
comes for the neonates who received antena-
tal corticosteroids or not is demonstrated in
Table 2. A significant reduction was noted in
the incidence of respiratory distress syndrome
in the treated group in relation to the group
not exposed to corticosteroids. Intra-hospital
death was also significantly reduced among
the patients that received antenatal corti-
costeroids, in comparison to those without the
medication. With regard to the secondary
outcomes observed in the present study, there
was a reduction in the need for surfactant
therapy and in the more severe peri-intraven-
tricular hemorrhage. The average number of
doses of exogenous surfactant (exposed group:
0.3 doses; non-exposed group: 0.6 doses; p =
0.010) and the average number of days on
mechanical ventilation (exposed group: 4 days;
non-exposed group: 6 days; p < 0.001) were
less among neonates who received antenatal
corticosteroid therapy.
With regard to the factors that influenced
the occurrence of respiratory distress syndrome
in the population studied, the following were
significant:
• Use of antenatal corticosteroids: this was a
significant protective factor against respi-
ratory distress syndrome (OR: 0.278; 95%
CI: 0.177-0.437). In the cohort studied,
the adjusted chance that a premature in-
fant not receiving antenatal corticosteroids
would develop respiratory distress syn-
drome was 3.7 times greater than for a
neonate exposed to the medication
• Gestational age: the chance that a child
in this cohort would develop respiratory
distress syndrome diminished by 1/0.75
(1.33) for each increase of one week in
gestational age at the time of its birth (OR:
0.758; 95% CI: 0.660-0.869)
• Weight: the chance that a newborn in the
present study would develop respiratory dis-
tress syndrome diminished by 1/0.99 (1.01)
for each increase of one gram in its birth
weight (OR: 0.999; 95% CI: 0.998-0.999)
• Apgar score of less than seven at the fifth
minute: the risk that a newborn with a
gestational age of less than 34 weeks and
an Apgar at the fifth minute of less than 7
would present respiratory distress syn-
drome was 2.48 times greater than for
neonates with an Apgar at the fifth minute
of greater than 7 (OR: 2.485; 95% CI:
1.370-4.506).
With regard to the factors that influenced
the number of intra-hospital deaths in the popu-
lation studied, the following were significant.
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• Prenatal care: the chance that a neonate
in the population studied whose mother
did not have prenatal care would die in
hospital was 1/0.503 (1.98) times the
chance for a child whose mother had four
or more prenatal care visits (OR: 0.503;
95% CI: 0.294-0.860).
• Gestational age: the chance that a child
in the study would die diminished by 1/
0.844 (1.18) for each additional week of
gestational age at the time of birth (OR:
0.844; 95% CI: 0.736-0.968).
• Birth weight: the chance that a child in
this cohort would die diminished by 1/
0.9989 (1.0011) for each addition of one
gram to the birth weight (OR: 0.998;
95% CI: 0.998-0.999).
• Respiratory distress syndrome: the pres-
ence of respiratory distress syndrome in
the population analyzed increased the
chance of intra-hospital death by a factor
of 1.68 (95% CI: 1.048-2.707).
• Necrotizing enterocolitis: this also consti-
tuted a significant risk factor, increasing
the risk of death almost threefold (OR:
2.594; 95% CI: 1.263-5.402).
• Mechanical ventilation: the chance that a
newborn in this cohort who needed me-
chanical ventilation would die in hospital
was 4.3 times greater than for infants who
did not need ventilatory support (OR:
4.318; 95% CI: 2.002-9.309).
• Apgar at fifth minute of less than 7: its
presence caused an almost fivefold increase
in the chance that a newborn in this co-
hort would die (OR: 4.709; 95% CI:
2.558-6.432).
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DISCUSSION
A retrospective cohort study was proposed
because the research would take in a period of
ten years during which technological advances
and improvements in the conditions of assist-
ance to neonates took place. Because of these
advances, the comparison of newborns who
received antenatal corticosteroid therapy or not
some years ago with those born in more recent
years would not be possible. The study would
need to be retrospective, because, as the ben-
efits of antenatal corticosteroid therapy on the
evolution of neonates had already been dem-
onstrated in the literature, it would not be pos-
sible to submit patients to a prospective study.
With regard to the rate of utilization of an-
tenatal corticosteroids at Hospital São Paulo/
Universidade Federal de São Paulo during the
period studied, the relatively frequent use of this
medication can be explained by the fact that this
hospital provides a referral service for high-risk
pregnant women and cases of elective prematu-
rity. That is, 40% to 50% of all the premature
births there correspond to planned prematu-
rity due to maternal or fetal problems.
Betamethasone was the medication of
choice for 99% of the patients. Because
betamethasone and dexamethasone present
similar structures and longer half-lives and cross
the placenta in a biologically active form, they
are the drugs most used in antenatal therapy.18
At present, betamethasone is the most recom-
mended drug for the induction of fetal matu-
ration61 because dexamethasone has been asso-
ciated with an increase in the risk for
periventricular leukomalacia.62 The corticoster-
oid doses prescribed by the obstetricians also
followed the general guidelines.4,17,18 In this way,
the findings from the present study in relation
to the utilization strategy for antenatal
corticosteroids were similar to those in the in-
ternational literature. This being so, the clini-
cal results to be expected also ought to be simi-
lar to those described for developed countries.
With regard to the maternal characteris-
tics (Table 1), it was noted that, in the group
exposed to the antenatal therapy, there was a
greater number of pregnant women with pre-
natal care, a greater frequency of pregnancy-
induced hypertension and cesarean sections.
These results reflect the fact that antenatal
corticosteroids are more frequently adminis-
tered in our context to women with adequate
prenatal care who present problems during the
pregnancy that often result in anticipated de-
livery. In addition to this, the number of pa-
tients who utilized tocolytics was greater in
the group exposed to antenatal corticosteroids,
with this finding being expected and in agree-
ment with data in the literature.33 This is be-
cause the women to whom tocolytics are ad-
ministered for the inhibition of premature
delivery labor end up receiving the associated
corticosteroid therapy.
In relation to the newborns (Table 1),
more infants that were small for the gestational
age were found in the group that received an-
tenatal corticosteroids, which may have con-
tributed towards a lower occurrence of respi-
ratory distress syndrome among the treated
patients. As the patients who received ante-
natal corticosteroids were those with compli-
cated pregnancies, the presence of a higher fre-
quency of neonates that were small for the
gestational age would be expected. In older
studies, it was demonstrated that fetal lung
maturation was accelerated in the presence of
maternal clinical situations that led to chronic
stress, thus promoting a lower incidence of
respiratory distress syndrome.63 On the other
Table 1. Demographic characteristics of the mothers and newborns exposed or
not exposed to antenatal corticosteroids, expressed by number of
patients (percentage) or mean (standard deviation)
EXPOSED NOT EXPOSED p
n = 205 n = 205
Maternal characteristics
Age (years) 27 (7) 26 (6) 0.141**
White race 133 (65%) 113 (55%) 0.055*
Prenatal care 132 (64%) 110 (54%) 0.034*
Pregnancy-induced hypertension 64 (31%) 37 (18%) 0.002*
Diabetes 11 (5%) 5 (2%) 0.202*
Use of tocolytics 45 (22%) 14 (7%) < 0.001*
Rupture of membranes > 24 hours 161 (79%) 151 (74%) 0.297*
Chorioamnionitis 11 (5%) 16 (8%) 0.425*
Cesarean section 124 (60%) 77 (38%) < 0.001*
Length of stay (days) 7 (8) 2    (3) < 0.001***
Neonatal characteristics
Weight (grams) 1289 (394) 1290 (389) 0.988**
Gestational age (weeks) 31 (2) 31 (3) 0.184**
Resuscitation † 182 (89%) 191 (93%)      0.167*
Apgar 1 6 (2) 5 (3) 0.009**
Apgar 5 8 (2) 8 (2) 0.097**
Small for gestational age 53 (26%) 34 (17%) 0.029*
Twinning 23 (11%) 26 (13%) 0.760*
* Chi-squared test ** Student’s t test *** Mann-Whitney test
† Resuscitation: need for free-flow oxygen and/or positive pressure ventilation and/or chest compressions and/
or cardiac medications in the delivery room.
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hand, later data indicated that when neonates
of the same gestational age are compared, the
small ones do not show advantages in terms
of a reduction in the incidence of respiratory
distress syndrome. Moreover, the small ones
present a greater need for mechanical ventila-
tion and more prolonged hospital stay, as well
as increased intra-hospital mortality.64,65
In the comparison of the Apgar score at
the first and fifth minutes between the patients
who received antenatal corticosteroids and
those who did not, the newborns exposed to
corticosteroid therapy presented a significantly
greater average Apgar score at the first minute
of life than those who were not. The higher
Apgar scores for patients who received ante-
natal corticosteroids probably reflect the role
that this class of medication plays in the car-
diovascular and respiratory stabilization of
premature neonates. Studies on animals have
shown evidence of the effect of corticosteroids
on the mechanisms for adaptation to extra-
uterine life. Stein et al.66 demonstrated, on
premature lambs, that corticosteroids led to
an improvement in ventilatory, circulatory and
metabolic functions of the animals treated,
which was related to the increase in the ade-
nyl-cyclase activity of the myocardium.
Corticosteroids are also thought to promote
an increase in the expression of adrenergic
receptors in vessel walls and the myocardium,
which assist in cardiocirculatory stabilization
at birth.24 This being so, the higher average
Apgar score at the first minute for patients
exposed to antenatal corticosteroid therapy,
observed in this study, may represent a greater
capacity among the premature infants for ad-
aptation to the extra-uterine environment.
In relation to the main clinical outcomes
for the newborns (Table 2), it was observed
that in this study antenatal corticosteroids had
a significant protective role, reducing the oc-
currence of respiratory distress syndrome in
the population studied by more than 50%. In
the latest revision of Crowley’s meta-analysis,30
the use of antenatal corticosteroids led to a
significant reduction in the incidence of res-
piratory distress syndrome, with the value of
the odds ratio (OR 0.53; 95% CI: 0.44-0.63)
being similar to what was found in the present
study. The large multicenter research projects
that have been done to evaluate the effect of
exogenous surfactants on the evolution of pre-
mature infants, which retrospectively analyzed
the data on the use of antenatal corticosteroids
in important American and Canadian
neonatal networks, also demonstrate the ben-
efits of corticosteroid therapy.34,67-69 In a gath-
ering-together of all these studies,70 involving
data on more than 35,000 newborns, it was
demonstrated that antenatal corticosteroids
significantly reduced the incidence of respira-
tory distress syndrome, with a non-adjusted
odds ratio of between 0.43 and 0.87.
Nonetheless, even with this positive re-
sult, the diminution of the incidence of respi-
ratory distress syndrome in neonates exposed
to antenatal corticosteroid therapy in our en-
vironment has to be analyzed in conjunction
with other factors that could be interfering in
the results. In the final logistic regression
model for the dependent variable “respiratory
distress syndrome”, the use of antenatal
corticosteroids persisted as a significant pro-
tection factor against the occurrence of respi-
ratory distress in the population analyzed. This
finding reinforces the protective role of ante-
natal corticosteroids in relation to respiratory
distress syndrome in our population. Taking
into account the high annual birth rates for
low-birth-weight and premature infants in
Brazil, and considering that respiratory prob-
lems and respiratory distress syndrome repre-
sent around 50% of the deaths during the
neonatal period,1 a more widespread use of
corticosteroid therapy could have a large im-
pact on specific neonatal mortality. In the lo-
gistic regression model for the variable of res-
piratory distress syndrome response, it was also
observed that greater gestational age and
higher birth weight had a significant protec-
tive role against the occurrence of respiratory
distress syndrome.
These data confirm what is shown in the
literature: low birth weight and younger ges-
tational age increase the risk of respiratory
distress syndrome and it is in this population
that antenatal corticosteroids exercise their
protective effect.61 This occurs even under
technological conditions for the care of ex-
tremely premature infants that are far from
those found in developed countries.
It was also observed that asphyxia (Apgar
at the fifth minute of less than 7) was a sig-
nificant risk factor for the occurrence of res-
piratory distress syndrome in the population
studied. In these circumstances, antenatal
corticosteroids would also exercise a protec-
tive role in cardiorespiratory stabilization at
birth66 and their contribution towards success-
ful adaptation to extra-uterine life would in-
directly influence the frequency of respiratory
distress syndrome, diminishing its occurrence.
The incidence of intra-hospital death
among patients who utilized antenatal
corticosteroids and those who did not was also
significantly lower in the treated group.
Crowley’s meta-analysis,30 which included
those born before and after exogenous sur-
factants became available, found an odds ra-
tio of 0.60 (95% CI: 0.48-0.75) for neonatal
mortality in relation to the utilization of an-
tenatal corticosteroids. However, in this meta-
analysis, the impact of antenatal corticoster-
oid therapy was lower among patients born
soon after 1980 (OR: 0.78; 95% CI: 0.54-
1.12), when the mortality due to respiratory
distress syndrome had not yet become so sig-
nificant and other factors may have exercised
greater influence on deaths among premature
infants in the developed countries.
In the present study, the fact that the
magnitude of the protective role of antenatal
steroids is close to that found during the pe-
riod before exogenous surfactants were avail-
able in developed countries reflects the
neonatal pattern ruling in Brazil: respiratory
affections are still an important cause of death
among newborns.1 However, when the use of
the medication was analyzed together with
other factors that could interfere in neonatal
mortality, antenatal corticosteroids did not
persist as a protective factor in the cohort stud-
ied. It is known that antenatal corticosteroids
increase the survival of neonates that previ-
ously would not have had the chance of sur-
vival. As a consequence, such patients come
Table 2. Clinical outcomes for newborns exposed or not exposed to antenatal corticosteroids
EXPOSED NOT EXPOSED OR 95% CI
number (%) number (%)
Respiratory distress syndrome 52 (25%) 101 (49%) 0.33 (0.21-0.51)
Need for mechanical ventilation 109 (53%) 128 (62%) 0.68 (0.45-1.03)
Need for surfactant 29 (14%) 63 (31%) 0.37 (0.22-0.62)
Bronchopulmonary dysplasia 26 (13%) 33 (16%) 0.76 (0.42-1.37)
Peri-intraventricular hemorrhage 58 (28%) 70 (34%) 0.67 (0.42-1.07)
Peri-intraventricular hemorrhage  III and IV 7 (12%)* 23 (33%)* 0.28 (0.10-0.77)
Necrotizing enterocolitis 19 (8%) 19 (9%) 1.00 (0.49-2.06)
Intra-hospital deaths 40 (20%) 66 (32%) 0.51 (0.38-0.82)
The comparisons between groups are expressed by the odds ratio and 95% confidence interval (CI).
* The percentage refers to the number of patients who presented the severe condition in relation to the number of
patients with peri-intraventricular hemorrhage.
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to present complications resulting from the
prolonged hospital stay, such as neonatal sep-
sis, necrotizing enterocolitis and chronic lung
disease, among others. Such complications, in
their turn, may contribute to neonatal mor-
tality. This being so, when all these factors are
analyzed together, the protective role of
corticosteroids in the survival of premature
infants may not be evident.
In the population studied, even though
this study was conducted in a tertiary-level
hospital, the mortality of premature infants
stratified by birth weight was significantly
higher than that reported in developed coun-
tries. Consequently, the influence of factors
like the absence of prenatal care, the presence
of perinatal asphyxia and prenatal and post-
natal infections, among others, may be more
important than the impact of the antenatal
corticosteroid therapy on neonatal mortality.
This speculation is, in a way, confirmed
in the present study, in observing the risk fac-
tors for the occurrence of intra-hospital death
in the cohort analyzed. These were the pres-
ence of respiratory distress syndrome and
necrotizing enterocolitis, the need for me-
chanical ventilation and the perinatal asphyxia.
It is worth emphasizing that the presence of
respiratory distress syndrome increased the
chance that a neonate from the population
studied would die, by a factor of 1.68. This
fact demonstrates that, even in the Neonatal
Unit of Hospital São Paulo, a tertiary-level
university facility that routinely uses mechani-
cal ventilation and has had exogenous
1. Maranhão AGK, Joaquim MMC, Siu C. Mortalidade perinatal
e neonatal no Brasil. Tema 1999;17:6-17.
2. Silva LK, Costa TP, Reis AF, Iamada NO, Azevedo AP,
Albuquerque CP. Avaliação da qualidade da assistência hospitalar
obstétrica: uso de corticóides no trabalho de parto prematuro.
Cad saúde pública 1999;15(4):817-29.
3. Liggins GC. Premature delivery of foetal lambs infused with
glucocorticoids. J Endocrinol 1969;45(4):515-23.
4. Liggins GC, Howie RN. A controlled trial of antepartum glu-
cocorticoid treatment for prevention of the respiratory distress
syndrome in premature infants. Pediatrics 1972;50(4):515-25.
5. Caspi E, Schreyer P, Weinraub Z, Reif R, Levi I, Mundel G.
Prevention of the respiratory distress syndrome in premature
infants by antepartum glucocorticoid therapy. Br J Obstet
Gynaecol 1976;83(3):187-93.
6. Block MF, Kling OR, Crosby WM. Antenatal glucocorticoid
therapy for the prevention of respiratory distress syndrome in
the premature infant. Obstet Gynecol 1977;50(2):186-90.
7. Morrison JC, Whybrew WD, Bucovaz ET, Schneider JM. In-
jection of corticosteroids into mother to prevent neonatal res-
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1978;131(4):358-66.
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CONTEXTO: Apesar de os benefícios da
corticoterapia antenatal estarem amplamente
demonstrados nos países desenvolvidos, há pou-
cos estudos envolvendo o uso do corticosteróide
antenatal nos neonatos brasileiros.
OBJETIVOS: Avaliar a efetividade do corti-
costeróide antenatal na evolução de recém-
nascidos prematuros com idade gestacional
inferior a 34 semanas.
TIPO DE ESTUDO: Estudo retrospectivo.
LOCAL: Hospital de atendimento terciário.
PARTICIPANTES: Recém-nascidos expostos a
qualquer dose de corticosteróide antenatal
para maturação fetal até sete dias antes do
parto e recém-nascidos pareados pelo sexo,
peso ao nascer, idade gestacional e época de
nascimento não expostos ao corticosteróide.
Obteve-se uma amostra de 205 expostos, 205
controles e 39 recém-nascidos expostos ao
corticosteróide antenatal para os quais não
foi possível encontrar um par não exposto.
PROCEDIMENTOS: Análise dos prontuários
maternos e dos recém-nascidos.
VARIÁVEIS ESTUDADAS: Compararam-se os
desfechos clínicos primários: incidência de
síndrome do desconforto respiratório e de
óbito intra-hospitalar nos dois grupos, além
de desfechos secundários relacionados à
morbidade neonatal.
RESULTADOS: O corticosteróide antenatal redu-
ziu a ocorrência da síndrome do desconforto
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respiratório (razão de chances, OR:0,33; in-
tervalo de confiança, IC, 95%:0,21-0,51) e o
efeito protetor persistiu quando ajustado para
o peso, idade gestacional e presença de asfixia
(OR ajustada:0,27; IC 95%: 0,17-0,43). O
efeito protetor pôde ser detectado também
através da redução da necessidade e do núme-
ro de doses de surfactante exógeno utilizadas e
do número de dias de ventilação mecânica nos
recém-nascidos expostos à corticoterapia
antenatal. O corticosteróide antenatal, quan-
do analisado isoladamente, reduziu a ocorrên-
cia do óbito intra-hospitalar (OR 0,51; IC
95%:0,38-0,82). No entanto, quando ajusta-
dos para o peso, a idade gestacional, a presen-
ça de pré-natal, asfixia, síndrome do descon-
forto respiratório, enterocolite necrosante e uso
de ventilação mecânica, o corticosteróide
antenatal não exerceu efeito protetor em rela-
ção ao óbito. Quanto aos outros desfechos, o
corticosteróide desempenhou papel protetor
para a hemorragia peri-intraventricular grave
(OR:0,28; IC 95%:0,10-0,77).
CONCLUSÕES: O corticosteróide antenatal foi
efetivo para a redução da morbimortalidade
de recém-nascidos prematuros na população
do estudo e o seu uso deve ser estimulado no
nosso meio.
PALAVRAS-CHAVE: Recém. Nascido. Prematu-
ro. Síndrome. Desconforto. Respiratório.
Corticosteróide. Antenatal.
Sao Paulo Med J 2003; 121(2):45-52.
